ABN 32 077 105 429 Level 1, 275 George Street, Sydney, NSW Australia

Tel: +61 2 9299 9270 Fax: +61 2 9299 9276

PRESENTATION

FOR IMMEDIATE RELEASE

4 December 2009

Australian healthcare company Stirling Products Limited (ASX:STI) is pleased release the Company’s Presentation prior to presentation at the “Invest in Australia: India” launch at the Sydney Hilton Hotel at 11.00 am this morning. Other presenters include: the Consul General for India, Westpac Bank, NSW Government Custom House/Western Union and Sustainable Energy Australasia. For further information see: www.stirlingproducts.net or contact Peter Boonen Managing Director Stirling Products Limited Ph: +61 2 9299 9270 E: peter.boonen@stirlingproducts.net Investor Relations inquiries please contact: James Moses Mandate Corporate Ph: +61 420 991 574 E: james@mandatecorporate.com.au

For

per

sona

l use

onl

y

(ASX:STI)

Presentation – 4 Dec 2009

“Invest in Australia: India”

Hilton Hotel Sydney NSW

For

per

sona

l use

onl

y

Forward looking statements...

This presentation provides only an overview of Stirling Products Limited ABN 32 077 105 429 (ASX:STI) and its opportunities. The information may require further explanation and/or clarification. Accordingly, this information should not be relied upon independently and should be considered in conjunction with past and future public information and announcements that are made by STI. Please contact STI and/or refer to the Company's website for further information.

The views expressed in this presentation may contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Stirling Products Limited’s control. These factors could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation. Because actual results may differ materially to assumptions made and STI’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

For

per

sona

l use

onl

y

About Stirling Products

• ASX listed: “STI”

• Healthcare & pharmaceutical Industry

• A Company in process of turn around & change

• Circa $11.5M market cap

• Asset backed – Offices and Pharma Plant*

*Subject to Court approval of Sale

For

per

sona

l use

onl

y

About Stirling Products

Core Business Interests Include:

• Extensive botanical product range – JV• Exclusive animal Health Products• Extensive patents over R-salbutamol

- Animal Growth promotion- Human Obesity

• Major drug inhalation delivery technology platform - JV

For

per

sona

l use

onl

y

2009 - Highlights

Stirling Products in 2009 has:

• new management• engaged industry, science & marketing experts• been re-positioned as a business within the

pharmaceutical and healthcare industry sector• Acquired freehold offices and production facility (in

process) which at value and/or replacement provide for value of circa $20M – approx $0.02 per share

2010 – targeting revenues: annualised $36M – by end Q4, – expecting over $5M in government grants– consummation of advanced relationship with major

pharma

For

per

sona

l use

onl

y

2009 – New Manufacturing Facility

4,310 sq m (46,400 sq ft) $20M Pharmaceutical Plant*

Laboratory

For

per

sona

l use

onl

y

2009 – New Manufacturing Facility

4,310 sq m (46,400 sq ft) $20M Pharmaceutical Plant*

One of the Plant’s filling and packaging lines

For

per

sona

l use

onl

y

Our Future

Our FUTURE is driven by our PERFORMANCE

Jan 2009 Dec 2009Share Price 0.003 0.013Market Cap $500k $11.5M Current Debt over $3M under $500kCash & Property approx $100k approx $3.3M

Stirling Products is today - underpinned by Assets incl:

• Freehold new pharmaceutical plant – *currently conditional• Own freehold offices

…. positioned for Significant Sales from Q1, 2010 and targeting:

- cash flow breakeven and profitability by mid 2010- annualised sales revenue of $36M+ by end 2010

For

per

sona

l use

onl

y

Our Future

2010 will be Stirling’s year of growth:• Focus on revenue realization starting with MLM• realization of sales targets - $36M by Dec 2010 • realization of major opportunities

- Products – pharma & botanicals- HDA platform

• joint ventures with major pharmas• continued aggressive growth

….and to also increase market awareness of Stirling Products Limited

- as a unique investment opportunity!

For

per

sona

l use

onl

y

First Products to Market...

Product launches in 2010 will include:

i•Naturals in Q1 All natural dietary supplements that target and optimize the Immune System for:

• ImmunoXel – for optimizing the immune system• Cholonorm – cholesterol health• Diabetin – blood sugar balance• Allergon – allergies

Adjuvant Immunomodulator• ImmunoXel/Dzherelo – for all strains of TB, TB/HIV co-infection and AIDS

following completion of further clinical trials in Nigeria, Ukraine and SA

Animal Health• ProVale – patented beta glucan feed additive that promotes health and

resistance to disease as well as growth promotion in production animals

For

per

sona

l use

onl

y

The Stirling product pipeline includes:

• R-Salbutamol – world’s only single enantiomer beta agonist patented for:

- growth promotion in livestock- human obesity

• High Density Aerosol (HDA) Drug Delivery Technology - Proven and patented platform technology that has demonstrated capability of improved delivery of many drugs through natural inhalation – this HDA platform provides Stirling the potential and opportunity of securing marketshare in a range of blockbuster drugs as they come off patent

Stirling Products in DevelopmentF

or p

erso

nal u

se o

nly

Key features of the HDA technology are:• Drug transport velocity - matched to the patient’s natural breathing• Reduced aerosol losses – less deposition on drug delivery pathways • Up to 3 times the aerosol concentration of other ultrasonic devices• Provides concentration level between that of dry powder inhalers and

conventional fan nebulizers• Delivered drugs – sub 5 micron – have much better & faster absorption• Active drug is in unique disposable capsules – competition protection• Testing has shown substantively less active

drug (than oral) is needed to provide the same benefit – potential for increased safety and less side effects

• Can potentially be used for administration of many major drugs

Stirling Products - HDA PlatformF

or p

erso

nal u

se o

nly

ImmunoXel - Immunomodulator

ImmunoXel has demonstrated in all its clinical trials that it:

• is a powerful immunomodulator and adjuvant• substantively optimizes the Immune System• enhances efficacy of - antibiotics, viral therapies

and chemotherapies• can substantially shorten drug and chemotherapy

treatment duration• can reduce and reverse treatment toxicity

side-effects – esp. in liver and kidneys• is market ready for treatment of TB, TB/HIV, AIDS • over 800 patients treated in clinical trials

– mainly TB, TB/HIV but also AIDS and influenza

• is a blockbuster product candidateFor

per

sona

l use

onl

y

ImmunoXel – Proven in TB

• Enhances efficacy of drugs 2-10 fold• Shortens therapy duration 3-12 fold• Reduces and reverses toxicity of current TB drugs• Is market ready for TB and TB/HIV treatment• Over 800 patients treated in clinical trials to date

“…a drug effective against drug-resistant TB can earn US$300 million a year…” - Global TB Alliance

Efficacy Treatment Time - Months

100

84

90

38

57

85

XDR

MDR

TB

ATT aloneImmunoxel

1

3

2

24

12

6

XDR

MDR

TB

ATT aloneImmunoxelF

or p

erso

nal u

se o

nly

Market Demand: TuberculosisF

or p

erso

nal u

se o

nly

ImmunoXel – Proven in AIDS Trials

In clinical trials when ImmunoXel was used as an adjuvant immunomodulator to anti-retroviral (ART) chemotherapy in the treatment of AIDS patients and compared to patients only on ART - ImmunoXel:

• Significantly increased CD3 T-lymphocytes• CD-4 T cell population almost doubled• The CD-4/CD-8 ratio increased 29.7%• CD-20 and B-lymphocytes declined to normal levels of around 333• CD-3, HLA-DR and T-cell population increased 216%• The CD3, CD16, CD56 and natural killer cells increased by 52.7%• 95% of all patients had decrease in viral load burden• Reduced and reversed toxicity side effects of ART• Is market ready for use as an AIDS ART adjuvant treatment

For

per

sona

l use

onl

y

Market Demand: AIDS

Estimated Number of People Living with HIV/AIDS, by Year

For

per

sona

l use

onl

y

Market Demand: Influenza

Although not specifically tested against the current swine flu strain of H1N1, Immunoxel has proven effective in warding off seasonal influenzas

For

per

sona

l use

onl

y

Stirling's Animal Products

ProVale – is a patented natural beta glucan that can increase animal survival rates and general health in intensive production operations such as those in the poultry, swine and aquaculture industries.

Extensive research has shown that highly purified beta 1,3/1,6 glucan will activate the innate and adaptive immune response in livestock and aquatic animals.

A healthy immune system will enable animals to better manage various environmental and disease pressures such as viruses, bacteria and parasites.

ProVale has also been shown to naturally promote animal growth and increase production survival rates.

For

per

sona

l use

onl

y

Development - ST-810 for Obesity

•ST- 810 is fully developed, chirally (molecular) pure, and has been safely used by humans for respiratory disease for over 15 years in its purified form and 30 years in its original formulation.

•Stirling is re-purposing this “old drug” for a “new use”- a well established product development process within the pharmaceutical industry

•ST- 810 is a “metabolic switch” that, in general terms, turns off the body’s fat production receptors and then lets the body naturally adjust its weight.

For

per

sona

l use

onl

y

Obesity - A Major Opportunity

In Australia - the total cost of obesity in 2008 was $58.2 billion which included the attributable cost of diseases such as diabetes, cardiovascular disease, various types of cancer and osteoarthritis.

- Weighing it Up: Obesity in AustraliaMay 2009 • House of Representatives Standing

Committee Report on Health and Ageing

In USA - “It's no secret that Americans are fat…Nearly one-third of U.S. adults are overweight, and another third are technically obese, as defined by a BMI (body-mass index) of more than 30. And Americans aren't happy about it. Last year, they spent an estimated $46 Billion on diet products.”

- Forbes Magazine

For

per

sona

l use

onl

y

Development - Growth Promoter

The measure of an animal’s efficiency in converting feed into body mass - the Feed Conversion Ratio (FCR) - is the kg of feed needed to produce one kg of increased animal weight.

There is arguably no more important aspect of animal production than the FCR...F

or p

erso

nal u

se o

nly

Development - Growth Promoter

R-Salbutamol – animal growth benefits withoutantibiotics or steroids as have been demonstrated

through animal trials

R-Salbutamol

21%

5%

70%

14%

17% 10%

11%

18%

5%

-7%-17%

-30%

Swine Poultry Sheep CattleFeed Efficiency Fat Content Weight Gain Lean Meat

For

per

sona

l use

onl

y

Commercialisation

The commercialisation process includes:• The launch of i•Naturals through an MLM

initiative, currently in progress, with the first region for release being in North America in Q1, 2010 and to be headed by a proven industry expert

• Joint venturing of products and/or technologies

• Licensing of products• Relationship establishment with governments in

areas of unmet need such as TB and HIV throughout the African continent - underway

• Pharmaceutical production (pending)

For

per

sona

l use

onl

y

Corporate

• Directors– Peter J. Boonen Managing Director– Neil Covey Director– Gulshan Jugroo CFO/Executive Director

• The Company’s corporate headquarters are in Sydney, Australia

• The Stirling commercial operations are based in Charlottetown, Canada

• South African and African operations are run through a joint venture (Stanimate) based in Johannesburg

• Further global joint venture operations are expected

For

per

sona

l use

onl

y

Stirling Scientific Expertise

Neil Covey – Extensive industry expertise. Former executive sales and marketing manager for Bayer (Aus.)

Dr Aldar Bourinbaiar – specialist in viral disease, discovered an AIDS treatment now used globally

Dr Galyna Kutsyna – a researcher and specialist in AIDS and viral disease

Dr Allen Bain – pharmacologist who cofounded an anti-arrhythmia drug being commercialised by Merck

Dr Manuel Carpio – Doctor of Veterinary Medicine

Dr Hinner Koster – specialist in animal nutrition and health

Dr Hugo Hattingh – specialist in animal nutrition and health

For

per

sona

l use

onl

y

Expectations

The Company’s strategy and direction in the immediate future is focused on:

• revenues – the i•Naturals product launch starting in the US by Q1 2010 and targeting breakeven by mid 2010 and minimum annualised sales of $36M by end 2010

• Initiate revenue generation opportunities for the new pharma plant – first agreement for $4.1M conditionally agreed

• aggressive product commercialisation especially our HDA drug delivery products

• partnering product development as well as marketing• realisation of one or more of our products as industry blockbusters

– esp. in human obesity• positioning the Company as an emergent, diverse and global

healthcare group• positioning the Company as a quality investment

For

per

sona

l use

onl

y

Summary

Our objectives are clearly ambitious for a small Company turn around situation.In a very short time-frame in 2009 we have achieved all of our targeted milestones ahead of schedule. We now have a unique position in that most of our products are:

• fully developed• market ready• meet existing and unmet health needsand we have:• our i•Natural range of dietary supplements being

launched in Q1, 2010• further products planned for 2010 launchesand:• our growth continues....

For

per

sona

l use

onl

y

Summary

On behalf of Stirling Products Limited and our growing team, I thank you for your interest and attention

Peter BoonenManaging Director

For

per

sona

l use

onl

y